Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors

NCT03228667 is registered in ClinicalTrials.gov with ImmunityBio, Inc. as lead sponsor.

NCT NCT03228667
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03228667 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
Lead sponsor
ImmunityBio, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 11, 2018
Completion date
December 31, 2030
Enrollment
40 (estimated)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer, colorectal cancer, gastric cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma, melanoma, merkel cell carcinoma, microsatellite instability, mismatch repair deficiency, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, urothelial carcinoma